A newly proposed semi-automated method of grading invasive lobular carcinoma: A unifying concept and correlation with prognostic markers and patient survival

Annals of Clinical and Laboratory Science

Volumn 39, Issue 1, 2009, Pages 25-31

  Stevens, Emily ^a   Kimler, Bruce F ^a   Davis, Marilyn K ^a   Fan, Fang ^a   Thomas, Patricia ^a   Wang, Xiao Yun ^a   Damjanov, Ivan ^a   Tawfik, Ossama W ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Invasive lobular carcinoma; Tumor grading

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; LYMPH NODE; MAJOR CLINICAL STUDY; MITOSIS RATE; NUCLEAR AND PROLIFERATION INDEX; PLOIDY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; SCARFF BLOOM RICHARDSON SYSTEM; STAINING; TUMOR VOLUME;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL PROLIFERATION; CHEMISTRY, CLINICAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 60249091189     PISSN: 00917370     EISSN: 15508080     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 2004; 6:R149-156.
2. Harake MD, Maxwell AJ, Sukumar SA. Primary and metastatic lobular carcinoma of the breast. Clin Rad 2001;56:621-630.
3. Yoder BJ, Wilkinson EJ, Massoll NA. Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast. Breast J 2007; 13:172-179.
4. Turashvili G, Bouchal J, Burkadze G, Kolar Z. Differentiation of tumours of ductal and lobular origin: I. Proteomics of invasive ductal and lobular breast carcinomas. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005;149:57-62.
5. Jayasinghe UW, Bilous AM, Boyages J. Is survival from infiltrating lobular carcinoma of the breast different from that of infiltrating ductal carcinoma? Breast J 2007; 13:479-485.
6. Tavassoli FA, Devilee P. World Health Organization Classification of Tumors. Pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon, 2003; pp 9-112.
7. Bloom HJ, Richardson WW. Histologic grading in breast cancer: a study of 1,409 cases of which 359 have been followed for 15 years. Br J Cancer 1957;11:359-377.
8. Bane AL, Tjan S, Parkes RK, Andrulis I, O'Malley FP. Invasive lobular carcinoma: to grade or not to grade. Mod Pathol 2005;18:621-628.
9. Brown RW, Allred CD, Clark GM, Osborne CK, Hilsenbeck SG. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 1996;2:585-592.
10. Boiesen P, Bendahl PO, Anangnostaki L, Domanski H, Holm E, Idvall I, Johansson S, Ljungberg O, Ringberg A, Ostberg G, Ferno M. Histologic grading in breast cancer: reproducibility between seven pathologic departments. South Sweden Breast Cancer Group. Acta Oncol 2000;39:41-45.
11. Delides GS, Garas G, Georgouli G, Jiortziotis D, Lecca J, Liva T, Elemenoglou J. Intralaboratory variations in the grading of breast carcinoma. Arch Pathol Lab Med 1982;106:126-128.
12. Harvey JM, de Klerk NH, Sterrett GF. Histological grading in breast cancer. Interobserver agreement and relation to other prognostic factors including ploidy. Pathology 1992;24:63-68.
13. Kronqvist P, Montironi R, Kuopio T, Collan YU. Subjective breast cancer grading. Analysis of reproducibility after application of Bayesian belief networks. Anal Quant Cytol Histol 1997;19:423-429.
14. Meyer JS, Alvarez C, Milikowski C, Olson N, Russo I, Russo J, Glass A, Zehnbauer BA, Lister K, Parwaresch R. Breast carcinoma malignancy grading by Bloom-Richardson system vs. proliferation index: reproducibility of grade and advantages of proliferation index. Mod Pathol 2005;18:1067-1078.
15. Tawfik O, Kimler BF, Davis M, Stasik C, Lai SM, Mayo MS, Fan F, Donahue JK, Damjanov I, Thomas P, Connor C, Jewell WR, Smith H, Fabian CJ. Grading invasive ductal carcinoma of the breast: advantages of using automated proliferation index instead of mitotic count. Virchows Arch 2007;450:627-636.
16. Tawfik O, Davis MK, Clark J, Fang F, Damjanov I, Namiq A,Thomas P, Kimler BF. A newly proposed semi- automated method of grading ductal carcinoma in situ of the breast. Mod Pathol 2006;19(Suppl 1):43A (abstract 187).
17. Martinez V, Azzopardi JG. Invasive lobular carcinoma of the breast: incidence and variants. Histopathology 1979;3:467-488.
18. Davis RP, Nora PF, Kooy RG, Hines JR. Experience with lobular carcinoma of the breast. Emphasis on recent aspects of management. Arch Surg 1979;114:485-488.
19. Smith DB, Howell A, Waqstaff J. Infiltrating lobular carcinoma of the breast: response to endocrine therapy and survival. Eur J Cancer Clin Oncol 1987;23:979-982.
20. Merkel DE, Osborne CK. Prognostic factors in breast cancer. Hematol Oncol Clin North Am 1989;3:641- 652.
21. Michaud LB. Treatment-experienced breast cancer. Am J Health Syst Pharm 2008;65:S4-9.
22. Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, Barry WT, Dressman HK, Ginsburg GS, Marcom KP, Garman KS, Lyman GH, Nevins JR, Potti A. Gene expression signatures, clinicopathologic features, and individualized therapy in breast cancer. JAMA 2008;299:1574-15 87.
23. Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobagyi GN. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 2008;13:477-493.
24. Yamashiro H, Toi M. Update of evidence in chemotherapy for breast cancer. Int J Clin Oncol 2008;13:2-7.
25. Sastre-Garau X, Jouve M, Asselain B, Vincent-Salomon A, Beuzeboc P, Dorval T, Durand JC, Fourquet A, Pouillart P. Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 1996;77:113-120.
26. Pinder SE, Murray S, Ellis IO, Trihia H, Elston CW, Gelber RD, Goldhirsch A, Lindtner J, Cortes-Funes H, Simoncini E, Byrne MJ, Golouh R, Rudenstam CM, Castiglione-Gertsch M, Gusterson BA. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy. Cancer 1998;83:1529-1539.
27. Gunther K, Merkelbach-Bruse S, Amo-Takyi BK, Handt S, Schroder W, Tietze L. Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization. J Pathol 2001;193:40-47.